![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ZNF347 |
Gene summary for ZNF347 |
![]() |
Gene information | Species | Human | Gene symbol | ZNF347 | Gene ID | 84671 |
Gene name | zinc finger protein 347 | |
Gene Alias | ZNF1111 | |
Cytomap | 19q13.42 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | A0A024R4L7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
84671 | ZNF347 | HCC1_Meng | Human | Liver | HCC | 1.28e-10 | -1.56e-02 | 0.0246 |
84671 | ZNF347 | HCC1 | Human | Liver | HCC | 1.30e-02 | 1.53e+00 | 0.5336 |
84671 | ZNF347 | HCC2 | Human | Liver | HCC | 3.82e-05 | 2.17e+00 | 0.5341 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZNF347 | SNV | Missense_Mutation | c.1867N>C | p.Glu623Gln | p.E623Q | Q96SE7 | protein_coding | deleterious(0.03) | benign(0.067) | TCGA-A2-A0YL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD | |
ZNF347 | SNV | Missense_Mutation | rs774457892 | c.2355N>C | p.Gln785His | p.Q785H | Q96SE7 | protein_coding | tolerated(0.21) | benign(0.347) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ZNF347 | SNV | Missense_Mutation | c.1216N>C | p.Glu406Gln | p.E406Q | Q96SE7 | protein_coding | deleterious(0.01) | probably_damaging(0.935) | TCGA-AC-A2FG-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | CR | |
ZNF347 | SNV | Missense_Mutation | c.797G>C | p.Gly266Ala | p.G266A | Q96SE7 | protein_coding | tolerated(0.12) | benign(0.033) | TCGA-B6-A0RG-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ZNF347 | SNV | Missense_Mutation | c.137C>T | p.Ser46Phe | p.S46F | Q96SE7 | protein_coding | tolerated(0.12) | probably_damaging(0.991) | TCGA-Z7-A8R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR | |
ZNF347 | SNV | Missense_Mutation | rs775214098 | c.1853N>A | p.Arg618Gln | p.R618Q | Q96SE7 | protein_coding | tolerated(0.06) | probably_damaging(0.929) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
ZNF347 | SNV | Missense_Mutation | c.634N>C | p.Glu212Gln | p.E212Q | Q96SE7 | protein_coding | tolerated(0.06) | possibly_damaging(0.578) | TCGA-DS-A1OC-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | gemcitabine | SD | |
ZNF347 | SNV | Missense_Mutation | novel | c.1417C>T | p.Leu473Phe | p.L473F | Q96SE7 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZNF347 | SNV | Missense_Mutation | c.182N>C | p.Leu61Ser | p.L61S | Q96SE7 | protein_coding | deleterious(0) | possibly_damaging(0.772) | TCGA-FU-A3HZ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR | |
ZNF347 | SNV | Missense_Mutation | rs761297771 | c.1765C>T | p.Arg589Trp | p.R589W | Q96SE7 | protein_coding | deleterious(0.04) | benign(0.04) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |